News › Industry News, News, Spotlights

Merz Aesthetics Invests in Regenerative Aesthetics Innovation, Leading Series A Funding of Acorn Biolabs

January 31, 2024
Merz Aesthetics

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, has made an investment in Acorn Biolabs by leading its Series A funding round. Acorn Biolabs is a personalized regenerative medicine company with offices in Toronto, Canada and Los Angeles. Acorn Biolabs offers the world’s first non-invasive, follicle-based, stem cell cryopreservation service and is developing treatments made from a client’s own cells. Terms were not disclosed.

“Merz Aesthetics is at the forefront of the emerging field of regenerative aesthetics, which seeks to stimulate the body’s own systems to repair and restore the structure and integrity of aging skin. We are looking to invest in opportunities that lie at the intersection of regenerative aesthetics and personalized medicine and our investment in Acorn Biolabs directly aligns with this strategy,” said Jon Parrish, PhD, chief corporate development officer at Merz Aesthetics.

Read more at Merz Aesthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
Advertisement